Nykode Therapeutics Denmark A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Bankruptcy risk for industry  1.5% 1.5% 1.5% 1.5% 1.5%  
Bankruptcy risk  0.0% 0.0% 3.5% 3.8% 2.8%  
Credit score (0-100)  0 0 52 51 59  
Credit rating  N/A N/A BBB BBB BBB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Gross profit  0.0 0.0 10,591 38,639 52,928  
EBITDA  0.0 0.0 1,064 3,657 5,041  
EBIT  0.0 0.0 763 2,613 3,833  
Pre-tax profit (PTP)  0.0 0.0 747.0 2,438.5 3,198.9  
Net earnings  0.0 0.0 578.1 1,895.4 2,484.5  
Pre-tax profit without non-rec. items  0.0 0.0 747 2,438 3,199  

 
See the entire income statement

Balance sheet (kDKK) 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Tangible assets total  0.0 0.0 0.0 0.0 697  
Shareholders equity total  0.0 0.0 978 2,874 5,358  
Interest-bearing liabilities  0.0 0.0 5,643 6,377 1,451  
Balance sheet total (assets)  0.0 0.0 10,954 14,830 20,504  

Net Debt  0.0 0.0 -4,265 1,492 -6,039  
 
See the entire balance sheet

Volume 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  0.0 0.0 10,591 38,639 52,928  
Gross profit growth  0.0% 0.0% 0.0% 264.8% 37.0%  
Employees  0 0 7 23 31  
Employee growth %  0.0% 0.0% 0.0% 228.6% 34.8%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  0 0 10,954 14,830 20,504  
Balance sheet change%  0.0% 0.0% 0.0% 35.4% 38.3%  
Added value  0.0 0.0 1,064.1 2,914.1 5,041.0  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  0 0 364 -1,629 4,910  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  0.0 0.0 1.0 2.0 3.0  

Profitability 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  0.0% 0.0% 7.2% 6.8% 7.2%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  0.0% 0.0% 7.1% 21.5% 21.8%  
ROI %  0.0% 0.0% 11.8% 34.8% 37.7%  
ROE %  0.0% 0.0% 59.1% 98.4% 60.4%  

Solidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Equity ratio %  0.0% 0.0% 8.9% 19.4% 26.1%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  0.0% 0.0% -400.8% 40.8% -119.8%  
Gearing %  0.0% 0.0% 576.9% 221.9% 27.1%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 1.3% 5.5% 16.8%  

Liquidity 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Quick Ratio  0.0 0.0 1.0 2.6 1.3  
Current Ratio  0.0 0.0 1.0 2.6 1.3  
Cash and cash equivalent  0.0 0.0 9,908.3 4,885.1 7,490.6  

Capital use efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  0.0 0.0 241.5 8,910.5 3,553.4  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2019
N/A
2020
N/A
2021
2021/12
2022
2022/12
2023
2023/12
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 152 127 163  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 152 159 163  
EBIT / employee  0 0 109 114 124  
Net earnings / employee  0 0 83 82 80